1Cardiologist, Imam Reza Hospital, Faculty of medicine, Mashhad University of Medical Sciences, Mashhad, Iran
2Resident of Cardiology, Imam Reza Hospital, Faculty of medicine, Mashhad University of Medical Sciences, Mashhad, Iran
Introduction: No-reflow phenomenon in coronary vessels, manifested in some patients with reperfused acute myocardial infarction (MI), is associated with poor clinical and functional outcomes. Therefore, evaluation of predisposing risk factors can be helpful in risk assessment and identification of patients at higher risk. Herein, we aimed to study the predictive factors for the development of no-reflow phenomenon in patients with ST-elevation acute MI (STEMI), following primary percutaneous coronary intervention (PCI). Materials and Methods: Overall, 141 patients with STEMI, treated with primary PCI, were enrolled in a cross sectional study.. Angiographic data associated with no-reflow phenomenon including thrombolysis in MI (TIMI) were evaluated. Patients were divided into study and control (TIMI grade 3) groups. Demographic, clinical and laboratory (lab) data including cardiovascular risk factors (e.g., diabetes, hypertension, hyperlipidemia , smoking), door-to-balloon time, serum creatinine and glucose levels, white and red blood cell counts (WBC and RBC counts, respectively), mean platelet volume (MPV), and red cell distribution width (RDW) were evaluated in both groups. Results: The mean age of the patients was 60.3±11.9 years. No-reflow was observed in 35 (24.8%) cases. WBC count, MPV , serum creatinine, BS, and high-density lipoprotein (HDL) levels were significantly correlated with TIMI flow Conclusion: Certain lab indices including MPV, WBC count, creatinine and HDL levels played significant independent roles in the no-reflow phenomenon. Thus, measuring such parameters might be helpful in predicting the risk of this condition in patients; however, further studies are required.
Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: aquantitative review of 23 randomised trials. Lancet. 2003;361:13-20.
Jacobs AK, Antman EM, Ellrodt G, Faxon DP, Gregory T, Mensah GA, et al. Recommendation to develop strategies to increase the number of ST-segment-elevation myocardial infarction patients with timely access to primary percutaneous coronary intervention. Circulation. 2006;113:2152-63.
Piana RN, Paik GY, Moscucci M, Cohen DJ, Gibson CM, Kugelmass AD, et al. Incidence and treatment of 'no-reflow' after percutaneous coronary intervention. Circulation. 1994;89:2514-8.
Morishima I, Sone T, Mokuno S, Taga S, Shimauchi A, Oki Y, et al. Clinical significance of no-reflow phenomenon observed on angiography after successful treatment of acute myocardial infarction with percutaneous transluminal coronary angioplasty. Am Heart J. 1995;130:239-43.
Resnic FS, Wainstein M, Lee MK, Behrendt D, Wainstein RV, Ohno-Machado L, et al. No-reflow is an independent predictor of death and myocardial infarction after percutaneous coronary intervention. Am Heart J. 2003;145:42-6.
Abbo KM1, Dooris M, Glazier S, O'Neill WW, Byrd D, Grines CL, et al. Features and outcome of no-reflow after percutaneous coronary intervention. Am J Cardiol. 1995 ;75:778-82.
Olafsson B1, Forman MB, Puett DW, Pou A, Cates CU, Friesinger GC, et al. Reduction of reperfusion injury in the canine preparation by intracoronary adenosine: importance of the endothelium and the noreflow phenomenon. Circulation. 1987;76:1135-45.
Paik GY, Caputo RP, Nunez BD. Thrombus contains soluble factors which decrease blood flow in swine coronary arteries through a nitrous oxide-dependent pathway. J Am Coll Cardiol 1994; 23: 64.
Celik T, Iyisoy A, Kursaklioglu H, et al. The impact of admission Creactive protein levels on the development of poor myocardial perfusion after primary percutaneous intervention in patients with acute myocardial infarction. Coron Artery Dis 2005;16:293–9.
Iwakura K, Ito H, Ikushima M, Kawano S, Okamura A, Asano K, et al. Association between hyperglycemia and the no-reflow phenomenon in patients with acute myocardial infarction. J Am Coll Cardiol 2003;41:1–7.
Jeong YH, Kim WJ, Park DW, Choi BR, Lee SW. Serum B-type natriuretic peptide on admission can predict the 'no-reflow' phenomenon after primary drug-eluting stent implantation for ST-segment elevation myocardial infarction.Int J Cardiol. 2010;141:175-81.
Booth G, Stalker TJ, Lefer AM, Scalia R. Elevated ambient glucose induces acute inflammatory events in the microvasculature: effects of insulin. Am J Physiol Endocrinol Metab 2001;280: 848–56.
Marfella R, Esposito K, Giunta R, Coppola G, De Angelis L, Farzati B, et al. Circulating adhesion molecules in humans: role of hyperglycemia and hyperinsulinemia. Circulation 2000;1012247–51.
Hokama JY, Ritter LS, Davis-Gorman G, Cimetta AD, Copeland JG,McDonagh PF. Diabetes enhances leukocyte accumulation in the coronary microcirculation early in reperfusion following ischemia. J Diabetes Complications 2000;14(4):96–107.
Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis.Circulation 2002;105:1135–43.
Kereikes DJ.Cultivating Prognosis Following Percutanous Coronary Intervention.J Am Coll Cardiol.2010;55:1933-1935.
Kodama T, Oida A, Kondo M, Kondo T, Arbustini E. Prevention of no-reflow phenomenon in culprit lesions involving a large side branch. Cardiovasc Interv Ther. 2014;77:442-4.
Brosh D, Assali AR, Mager A, Porter A, Hasdai D.of no-reflow during primary percutaneous coronary intervention for acute myocardial infarction on six-month mortality. Am J Cardiol. 2007;99:442-5.
Martin JF, Towbridge EA, Salmon GL, Plumb J. The biologicalsignificance of platelet volume: its relationship to bleeding time,platelet thromboxane B2 production and megacaryocyte nuclear DNA concentration. Thromb Res. 1983;32:443-60.
Huczek Z, Kochman J, Filipiak KJ, Horszczaruk GJ, Grabowski M.Mean platelet volume on admission predicts impaired reperfusion and long-term mortality in acute myocardial infarction treated with primary percutaneous coronary intervention. J Am Coll Cardiol. 2005;46:284-90.